Following a busy few months, Capsugel spoke about the formation of its Dosage Form Solutions Unit, its technology and the integration of Encap at this year’s Interphex in New York.
According to Aresh Tahbez, the Director of Global Marketing at Capsugel’s recently formed Dosage Forms Solutions (DFS) Unit, the Unit is built upon three areas: Capsugel’s technologies, its R&D capabilities and its manufacturing infrastructure.
Federal Reserve Bank of Boston President Eric Rosengren said regional collaboration between cities and government agencies is a “crucial factor” in strengthening the economies of smaller cities.
“We need more public-private cooperation, collaboration, and investment aimed at removing the barriers that are holding back our smaller and medium sized cities,” Ben Hecht, president of Living Cities Inc., a philanthropic organization that is also helping to fund the initiative, said in the statement today.
Can you give a brief introduction to the mammalian target of rapamycin (mTOR) pathway?
The mammalian target of rapamycin, mTOR is a central integrator of the cell that coordinates growth factor receptor signaling with energy and nutrient status to control a wide array of activities, including the regulation of cellular proliferation and survival. Thus, mTOR has emerged as a compelling cancer drug target, particularly for glioblastoma, the most common and lethal form of adult brain cancer.